ARO-C3
AROC3-1001
Phase 2 small_molecule active
Quick answer
ARO-C3 for complement-mediated renal disease is a Phase 2 program (small_molecule) at Arrowhead Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arrowhead Pharmaceuticals Ireland Limited
- Indication
- complement-mediated renal disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active